Politics House Dems sound alarm about Trump health nominee

01:06  09 january  2018
01:06  09 january  2018 Source:   thehill.com

White House re-nominates McFarland despite Democrats' warnings

  White House re-nominates McFarland despite Democrats' warnings The White House decided to re-nominate a former deputy national security adviser for an administrative post despite warnings from Democrats they are unlikely to support her amid questions about previous congressional testimony. On Monday, the White House re-submitted dozens of names to the Senate for administration posts after their nominations expired at the end of last year. Included in the slate: K.T. McFarland, the national security pundit and one-time deputy national security adviser who President Donald Trump tapped to become the US ambassador to Singapore.

with new abortion restrictions Dems press Trump officials to reduce price of opioid reversal drug Overnight Defense: House panel passes 6B defense bill | What's in the bill and what didn't O’Rourke is running for the Senate in Texas and is expected to be the Democratic nominee to take on Sen.

House Dems sound alarm about Trump health nominee . There are fewer federal OSHA inspectors under the Trump administration, raising concerns about the impact on worker health and safety.

a man wearing glasses posing for the camera © Provided by The Hill A group of House Democrats want the Senate Finance Committee to question President Trump's nominee for Health and Human Services secretary about high drug prices at his former employer, Eli Lilly.

In a letter to Finance Committee leaders, led by Texas Reps. Beto O'Rourke and Lloyd Doggett, the Democrats also said Alex Azar should also be pressed on his commitment to uphold the Affordable Care Act, otherwise known as ObamaCare.

Azar is scheduled to appear before the Senate Finance Committee for a confirmation hearing on Tuesday.

This won't be the first time in the hot seat for Azar, who faced the Senate Health Committee last month in what was billed as a courtesy hearing. But this time, he'll be before the Senate Finance Committee, which will make the decision about whether to send his nomination to the Senate floor.

Former GOP rep: Trump's mental health 'a grave conversation'

  Former GOP rep: Trump's mental health 'a grave conversation' Former Rep. David Jolly (R-Fla.) on Monday said the national discussion about President Trump's mental stability is a "grave conversation" that it is "challenging for the country.""This is a very grave conversation. It has been over 30 years since this nation had a conversation about whether or not our president was fit to serve," Jolly told host Nicole Wallace on MSNBC's "Deadline White House.

A group of House Democrats want the Senate Finance Committee to question President Trump 's nominee for Health and Human Services secretary about high drug prices at his former employer, Eli Lilly.

Senate Majority Leader Mitch McConnell Addison (Mitch) Mitchell McConnell Lawmakers feel pressure on guns Bipartisan group of House lawmakers urge action on Export-Import Bank nominees Curbelo Dem rival lashes out over immigration failure MORE (R-Ky

Democrats are expected to question Azar on how he would lower the cost of prescription drugs, given his background as a former pharmaceutical executive. They also want to hear his  views on a variety of other issues, including ObamaCare, block grants for Medicaid and women's health.

Azar worked at the pharmaceutical company Eli Lilly for nearly a decade, serving most recently as the president of Lilly USA, a post he left last January. The company reportedly substantially increased the price of insulin while Azar was there, from $123 per vial in 2012 to $255 per vial in 2017.

In their letter, the House lawmakers said "Azar's history as a top executive at Eli Lilly when drug prices rose exorbitantly, along with his recent statements about the ACA, demonstrate that he may not meet" the highest standards needed to be the leader of the country's health care system.

The House members posed a number of questions they hoped Azar would answer about the types of reforms he wants to see from the drug industry, as well as his ideas for lowering drug prices and increasing industry transparency.

The letter also said Azar has made "troubling" statements about ObamaCare in the past. They urged Finance Committee members to press him on whether he will "defend and implement the Affordable Care Act as the law of the land."

O'Rourke is running for the Senate in Texas and is expected to be the Democratic nominee to take on Sen. Ted Cruz (R) in November.

Hawaii reps call for hearing on missile alerts after false alarm .
Two U.S. Representatives from Hawaii have requested a panel hearing to discuss whether the state should remain in charge of sending emergency incoming missile alerts, following a false alarm sent out to people in the state on Saturday.Reps. Tulsi Gabbard (D) and Colleen Hanabusa (D) requested that the House Armed Services Committee holds a hearing in a letter sent Tuesday, suggesting that Hawaii's Emergency ManagemeReps. Tulsi Gabbard (D) and Colleen Hanabusa (D) requested that the House Armed Services Committee holds a hearing in a letter sent Tuesday, suggesting that Hawaii's Emergency Management Agency should retain control of disasters other than incoming missiles, which is a national security issue.

—   Share news in the SOC. Networks

Topical videos:

This is interesting!